The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Trastuzumab-modified nanoparticles: Optimisation of preparation and uptake in cancer cells
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Slamon, D. J., Clark, G. M., Wong, S. G., Levin, W. J., Ullrich, A., & McGuire, W. L. (1987) · Science · doi:10.1126/science.3798106 · Cited by 11,760
Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review
Maeda, H., Wu, J., Sawa, T., Matsumura, Y., & Hori, K. (2000) · Journal of Controlled Release · doi:10.1016/s0168-3659(99)00248-5 · Cited by 6,565
Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets
Clynes, R. A., Towers, T. L., Presta, L. G., & Ravetch, J. V. (2000) · Nature Medicine · doi:10.1038/74704 · Cited by 2,768
Cited by
Active targeting schemes for nanoparticle systems in cancer therapeutics
Byrne, J. D., Betancourt, T., & Brannon-Peppas, L. (2008) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2008.08.005 · Cited by 1,731
Albumin-based nanoparticles as potential controlled release drug delivery systems
Elzoghby, A. O., Samy, W. M., & Elgindy, N. A. (2012) · Journal of Controlled Release · doi:10.1016/j.jconrel.2011.07.031 · Cited by 1,520
Nicolas, J., Mura, S., Brambilla, D., Mackiewicz, N., & Couvreur, P. (2013) · Chem. Soc. Rev. · doi:10.1039/c2cs35265f · Cited by 1,270
Mishra, B., Patel, B. B., & Tiwari, S. (2010) · Nanomedicine: Nanotechnology, Biology and Medicine · doi:10.1016/j.nano.2009.04.008 · Cited by 771
Cancer active targeting by nanoparticles: a comprehensive review of literature
Bazak, R., Houri, M., El Achy, S., Kamel, S., & Refaat, T. (2015) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-014-1767-3 · Cited by 756
Harnessing albumin as a carrier for cancer therapies
Hoogenboezem, E. N., & Duvall, C. L. (2018) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2018.07.011 · Cited by 610
Ulbrich, K., Hekmatara, T., Herbert, E., & Kreuter, J. (2009) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2008.08.021 · Cited by 591
Particle shape enhances specificity of antibody-displaying nanoparticles
Barua, S., Yoo, J.-W., Kolhar, P., Wakankar, A., Gokarn, Y. R., & Mitragotri, S. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1216893110 · Cited by 523
“3-fold enhancement in uptake of polylactic acid (PLA) or PLGA nanoparticles by SK-BR-3 cells (11, 33, 34); and 2–3-fold increase in uptake of albumin nanoparticles by BT-474 and SK-BR-3 cells (20).”
BackgroundCellular responses to nanoparticles: Target structures and mechanisms
Unfried, K., Albrecht, C., Klotz, L.-O., Von Mikecz, A., Grether-Beck, S., & Schins, R. P. F. (2007) · Nanotoxicology · doi:10.1080/00222930701314932 · Cited by 503
Sahu, T., Ratre, Y. K., Chauhan, S., Bhaskar, L. V. K. S., Nair, M. P., & Verma, H. K. (2021) · Journal of Drug Delivery Science and Technology · doi:10.1016/j.jddst.2021.102487 · Cited by 487
Jeyaraj, M., Gurunathan, S., Qasim, M., Kang, M.-H., & Kim, J.-H. (2019) · Nanomaterials · doi:10.3390/nano9121719 · Cited by 481
Targeting cancer cells using PLGA nanoparticles surface modified with monoclonal antibody
Kocbek, P., Obermajer, N., Cegnar, M., Kos, J., & Kristl, J. (2007) · Journal of Controlled Release · doi:10.1016/j.jconrel.2007.03.012 · Cited by 436
Albumin nanostructures as advanced drug delivery systems
Karimi, M., Bahrami, S., Ravari, S. B., Zangabad, P. S., Mirshekari, H., Bozorgomid, M., Shahreza, S., Sori, M., & Hamblin, M. R. (2016) · Expert Opinion on Drug Delivery · doi:10.1080/17425247.2016.1193149 · Cited by 422
Suzuki, T., Ishii-Watabe, A., Tada, M., Kobayashi, T., Kanayasu-Toyoda, T., Kawanishi, T., & Yamaguchi, T. (2010) · The Journal of Immunology · doi:10.4049/jimmunol.0903296 · Cited by 368
New frontiers in nanotechnology for cancer treatment
Alexis, F., Rhee, J.-W., Richie, J. P., Radovic-Moreno, A. F., Langer, R., & Farokhzad, O. C. (2008) · Urologic Oncology: Seminars and Original Investigations · doi:10.1016/j.urolonc.2007.03.017 · Cited by 347
Stimuli‐responsive nanotherapeutics for precision drug delivery and cancer therapy
Qiao, Y., Wan, J., Zhou, L., Ma, W., Yang, Y., Luo, W., Yu, Z., & Wang, H. (2019) · WIREs Nanomedicine and Nanobiotechnology · doi:10.1002/wnan.1527 · Cited by 332
Antibody‐Conjugated Nanoparticles for Biomedical Applications
Arruebo, M., Valladares, M., & González-Fernández, Á. (2009) · Journal of Nanomaterials · doi:10.1155/2009/439389 · Cited by 331
Protein Nanoparticles: Promising Platforms for Drug Delivery Applications
Jain, A., Singh, S. K., Arya, S. K., Kundu, S. C., & Kapoor, S. (2018) · ACS Biomaterials Science & Engineering · doi:10.1021/acsbiomaterials.8b01098 · Cited by 308
Rekindling RNAi Therapy: Materials Design Requirements for In Vivo siRNA Delivery
Kim, B., Park, J., & Sailor, M. J. (2019) · Advanced Materials · doi:10.1002/adma.201903637 · Cited by 298
Trewyn, B. G., Nieweg, J. A., Zhao, Y., & Lin, V. S.-Y. (2008) · Chemical Engineering Journal · doi:10.1016/j.cej.2007.09.045 · Cited by 275
Biodegradable, polymeric nanoparticle delivery systems for cancer therapy
Pridgen, E. M., Langer, R., & Farokhzad, O. C. (2007) · Nanomedicine · doi:10.2217/17435889.2.5.669 · Cited by 249
Active targeting drug delivery nanocarriers: Ligands
Salahpour Anarjan, F. (2019) · Nano-Structures & Nano-Objects · doi:10.1016/j.nanoso.2019.100370 · Cited by 196
Huang, R., Sun, Y., Zhang, X.-Y., Sun, B.-W., Wang, Q.-C., & Zhu, J. (2015) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2015.05.013 · Cited by 21
Metadata
- Authors
- Steinhauser, I., Spänkuch, B., Strebhardt, K., & Langer, K.
- Venue
- Biomaterials
- Publisher
- Elsevier BV
- Published
- 2006-10
- Volume
- 27
- Issue
- 28
- Pages
- 4975-4983
- ISSN
- 0142-9612 (ISSN-L)
- OpenAlex
- W2087324070
- Cited by
- 216
- References
- 3
- FWCI
- 6.29
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.